PLAY PODCASTS
Expert Insights on Optimal Current Management of Patients With Cholangiocarcinoma
Episode 117

Expert Insights on Optimal Current Management of Patients With Cholangiocarcinoma

In an engaging discussion, Christine Chio, PharmD, BCOP; Lipika Goyal, MD; and Caroline Kuhlman, NP, share how they currently treat patients with cholangiocarcinoma, including initial diagnosis, biomarker testing to guide treatment, adverse event management, and patient counseling.

Decera Clinical Education Oncology Podcast · Caroline Kuhlman NP, Lipika Goyal MD, Christine Chio PharmD BCOP

March 21, 202234m 1s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode, Lipika Goyal, MD, leads an engaging discussion with Christine Chio, PharmD, BCOP, and Caroline Kuhlman, NP, on current treatment of patients with cholangiocarcinoma. Topics include:

  • Initial diagnosis
  • Biomarker testing to guide treatment with immunotherapies and targeted agents
  • Adverse event management
  • Strategies for counseling patients

Presenters:

Christine Chio, PharmD, BCOP
Clinical Ambulatory GI Oncology Pharmacist
Department of Pharmacy
Massachusetts General Hospital
Boston, Massachusetts

Lipika Goyal, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Harvard Medical School
Attending Physician
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Caroline Kuhlman, NP
Department of Gastrointestinal Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Link to the full program on the CCO website: 
https://bit.ly/3JGDBCk

 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

extrahepaticfgfr2entrectinibmsi highadverse eventhyperphosphatemiafgfr inhibitorspemigatinibtopaz-1pembrolizumabmypathwaybraf v600elarotrectinibher2tumor mutational burdenliver cancerbile duct cancerivosidenibbiomarkersabc-02gall bladderinfigratinibimmunotherapydurvalumabidh1canceradherenceswog 1815